Showing results (791-800 of 834) with videos related to

Sort By:
Pageof 84
Annals of Gastroenterological Surgery|July 3, 2026
Annual Report of the 2022 National Clinical Database: Decade-Long Trends and Current Status of Gastroenterological Surgery in JapanKoshi Kumagai, Arata Takahashi, Hideki Ueno, et al.
Journal of Gastroenterology|April 25, 2013
Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patientsYuki Ohishi, Makoto Nakamuta, Naoko Ishikawa, et al.
Scientific Reports|May 12, 2021
Thyroid hormone activated upper gastrointestinal motility without mediating gastrointestinal hormones in conscious dogsNobuhiro Nakazawa, Makoto Sohda, Kyoichi Ogata, et al.
Annals of Surgical Oncology|October 2, 2019
High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint InhibitorsNobuhiro Nakazawa, Takehiko Yokobori, Kyoichi Kaira, et al.
American Journal of Translational Research|November 13, 2018
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lungYoichi Ohtaki, Kyoichi Kaira, Jun Atsumi, et al.
Annals of Surgical Oncology|September 4, 2015
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)Eiji Oki, Yasunori Emi, Yuji Miyamoto, et al.
Annals of Gastroenterological Surgery|January 6, 2025
Annual report on National Clinical Database 2021 for gastroenterological surgery in JapanSunao Ito, Arata Takahashi, Hideki Ueno, et al.
Annals of Surgical Oncology|September 3, 2024
Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter StudyNobuhiro Nakazawa, Makoto Sohda, Nobuhiro Hosoi, et al.
Anticancer Research|June 26, 2024
Risks and Outcomes of Early Dose Reduction in Adjuvant CAPOX Therapy for Colorectal CancerIkuma Shioi, Hiroomi Ogawa, Ryozan Naito, et al.
Oncology|September 12, 2024
Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter StudyNobuhiro Nakazawa, Makoto Sohda, Nobuhiro Hosoi, et al.
Pageof 84